Today: 9 June 2026
Nestle stock faces Monday test after France probes baby deaths tied to recalled formula
25 January 2026
1 min read

Nestle stock faces Monday test after France probes baby deaths tied to recalled formula

Zurich, Jan 25, 2026, 19:58 CET — Market closed.

  • On Friday, Nestle shares ended the session down 1.0%, closing at 72.47 Swiss francs.
  • France is investigating two infant deaths linked to formula that had been subject to precautionary recalls.
  • Traders await investigative findings due in the coming days, along with Nestle’s results on Feb. 19.

Nestle shares face pressure as Swiss markets open Monday, following French authorities launching investigations into the deaths of two infants linked to baby formula from precautionary recalls.

The Swiss food group’s shares ended the session down 0.98%, closing at 72.47 Swiss francs. This price point could expose the stock to fresh headline-driven swings once trading restarts.

This is critical now since infant nutrition hinges on trust, and the incident keeps Nestle under scrutiny while it struggles to contain an expanding formula recall. The longer the problem drags on, the more investors prepare for higher expenses, sales declines, or increased regulatory pressure.

This also comes before Nestle’s next big event: the full-year results set for Feb. 19.

French investigators are looking into whether the deaths are connected to the products, but the health ministry says no causal link has been found yet. The recalls involve potential contamination with cereulide, a toxin known to cause nausea and vomiting.

Nestle rejected any connection between its products and the deaths, stating in an email: “at this stage nothing indicates any link between these tragic events and the consumption of our products.” Reuters

On Friday, shares moved within a tight band from 71.96 to 73.07 francs but closed down, market data show. This limited fluctuation hints that investors haven’t sharply adjusted their risk outlook — at least not so far.

The problem isn’t limited to Nestle. Lactalis has pulled infant milk from shelves in several countries, while Danone has flagged concerns over a batch destined for Singapore. This points to a wider supply-chain issue in the sector.

Traders will be closely monitoring any updates from prosecutors and ministries in the week ahead, looking for clues on whether the recall perimeter will expand or hold steady. France’s farm ministry said it expects results from an initial judicial inquiry within the next 10 days.

Macro factors remain in play. On Monday, Switzerland’s central bank will release “important monetary policy data,” a report likely to influence the franc and shape rate expectations crucial to global giants such as Nestle. Swiss National Bank Data Portal

The path is straightforward. Should investigators come up empty and the recall fade, the stock might shift back to focusing on rates and earnings forecasts. But if a connection is proven, legal risks and reputational harm could escalate quickly, prompting investors to factor in a prolonged drop in volumes.

Next on the docket: official findings from France expected within the 10-day timeframe, followed by Nestle’s February 19 earnings release. Management will need to address the financial fallout and confirm if the disruption is under control.

Stock Market Today

  • S&P 500 Rallies on Chipmaker Gains; Crude Oil Prices Retreat After Iran-Israel Ceasefire Signal
    June 9, 2026, 9:24 AM EDT. The S&P 500 gained +0.30% on Monday, driven by renewed investor interest in artificial intelligence boosting chipmakers. Nasdaq 100 rose +1.58%, while the Dow slipped -0.16%, dragged lower by Apple's -1% drop amid lukewarm AI platform feedback. Crude oil prices surged over +4% initially due to Iran-Israel tensions but retreated after Iran signaled an end to its current military operation. The market discounts a low 3% chance of a +25 basis point rate hike by the Federal Reserve on June 16-17. Treasury yields climbed, with 10-year notes reaching a two-week high of 4.58%, pressured by strong US jobs data and heavy upcoming Treasury auctions. Overseas markets closed mixed, with China's Shanghai Composite down -1.70% and Japan's Nikkei falling -3.85%.

Latest articles

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

9 June 2026
Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
Micron stock hovers near $400 as Intel flags memory cost pressure; Fed decision next
Previous Story

Micron stock hovers near $400 as Intel flags memory cost pressure; Fed decision next

Zhongji Innolight (300308.SZ) stock: China’s new fund-favorite faces a Monday test after a 5.8% slide
Next Story

Zhongji Innolight (300308.SZ) stock: China’s new fund-favorite faces a Monday test after a 5.8% slide

Go toTop